Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality

P.M. Dodson

Research output: Contribution to journalReview article

Abstract

Diabetic eye disease confers substantial burden on the patient quality of life. Current therapeutic strategies indicate an unmet clinical need for preventive therapy. Tight control of blood pressure and glycaemia are mandatory components of primary prevention strategies, but are insufficient to eliminate risk in all patients. A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Although inconclusive for statin therapy, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy. However, there is a need for confirmation of these findings in large prospective studies with progression of retinopathy as the primary endpoint, such as the ACCORD-EYE (Action to Control Cardiovascular Risk in Diabetes-EYE) study, and in a clinical trial specifically conducted for diabetic maculopathy. In addition, elucidation of the mechanism(s) of effect of fenofibrate is indicated.

Original languageEnglish
Pages (from-to)997-1003
Number of pages7
JournalEye
Volume23
Issue number5
Early online date23 Jan 2009
DOIs
Publication statusPublished - May 2009

Fingerprint

Diabetic Retinopathy
Fenofibrate
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Eye Diseases
Laser Therapy
Primary Prevention
Therapeutics
Disease Progression
Quality of Life
Clinical Trials
Prospective Studies
Blood Pressure

Keywords

  • diabetic retinopathy
  • fenofibrate
  • FIELD
  • lipid-lowering
  • macular oedema
  • treatment

Cite this

@article{674216d38e9f418287c703e146deb2ec,
title = "Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality",
abstract = "Diabetic eye disease confers substantial burden on the patient quality of life. Current therapeutic strategies indicate an unmet clinical need for preventive therapy. Tight control of blood pressure and glycaemia are mandatory components of primary prevention strategies, but are insufficient to eliminate risk in all patients. A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Although inconclusive for statin therapy, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy. However, there is a need for confirmation of these findings in large prospective studies with progression of retinopathy as the primary endpoint, such as the ACCORD-EYE (Action to Control Cardiovascular Risk in Diabetes-EYE) study, and in a clinical trial specifically conducted for diabetic maculopathy. In addition, elucidation of the mechanism(s) of effect of fenofibrate is indicated.",
keywords = "diabetic retinopathy, fenofibrate, FIELD, lipid-lowering, macular oedema, treatment",
author = "P.M. Dodson",
year = "2009",
month = "5",
doi = "10.1038/eye.2008.428",
language = "English",
volume = "23",
pages = "997--1003",
journal = "Eye",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "5",

}

Management of diabetic retinopathy : could lipid-lowering be a worthwhile treatment modality. / Dodson, P.M.

In: Eye, Vol. 23, No. 5, 05.2009, p. 997-1003.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Management of diabetic retinopathy

T2 - could lipid-lowering be a worthwhile treatment modality

AU - Dodson, P.M.

PY - 2009/5

Y1 - 2009/5

N2 - Diabetic eye disease confers substantial burden on the patient quality of life. Current therapeutic strategies indicate an unmet clinical need for preventive therapy. Tight control of blood pressure and glycaemia are mandatory components of primary prevention strategies, but are insufficient to eliminate risk in all patients. A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Although inconclusive for statin therapy, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy. However, there is a need for confirmation of these findings in large prospective studies with progression of retinopathy as the primary endpoint, such as the ACCORD-EYE (Action to Control Cardiovascular Risk in Diabetes-EYE) study, and in a clinical trial specifically conducted for diabetic maculopathy. In addition, elucidation of the mechanism(s) of effect of fenofibrate is indicated.

AB - Diabetic eye disease confers substantial burden on the patient quality of life. Current therapeutic strategies indicate an unmet clinical need for preventive therapy. Tight control of blood pressure and glycaemia are mandatory components of primary prevention strategies, but are insufficient to eliminate risk in all patients. A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Although inconclusive for statin therapy, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy. However, there is a need for confirmation of these findings in large prospective studies with progression of retinopathy as the primary endpoint, such as the ACCORD-EYE (Action to Control Cardiovascular Risk in Diabetes-EYE) study, and in a clinical trial specifically conducted for diabetic maculopathy. In addition, elucidation of the mechanism(s) of effect of fenofibrate is indicated.

KW - diabetic retinopathy

KW - fenofibrate

KW - FIELD

KW - lipid-lowering

KW - macular oedema

KW - treatment

UR - https://www.nature.com/eye/journal/v23/n5/full/eye2008428a.html

UR - http://www.scopus.com/inward/record.url?scp=65949123780&partnerID=8YFLogxK

U2 - 10.1038/eye.2008.428

DO - 10.1038/eye.2008.428

M3 - Review article

C2 - 19169236

AN - SCOPUS:65949123780

VL - 23

SP - 997

EP - 1003

JO - Eye

JF - Eye

SN - 0950-222X

IS - 5

ER -